Openbookopenbook
Equity
Cronos Group Inc(CRON)
USD --+0.00%
Reward61Moderate
Risk35Moderate
📊75%Data
Strong 27% profit margin
CRON
+0.0 · +0.00%
USD · NASDAQ
Cronos Group Inc | Healthcare
Profitless Growth
Market Cap:1.01Bn
ℹ️
Reward Rating
61
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
35
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on CRON to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $2.33.

What is Cronos Group Inc?

, a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally.

CRON · Verdict

Solid reward · moderate risk

CRON stands out on balance sheet and growth, but watch the profitability signal.

Based on 88% data coverage

CRON · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet93/100

    Current ratio 18.84

  • Growth92/100

    Revenue +22.1% CAGR

Watchouts 2

  • Profitability28/100

    35% net margin · 4% ROE

  • Valuation44/100

    P/E 32.6×

Model-based scoring. For information only — not financial advice.

What is Cronos Group Inc?

, a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brand names. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.01B, and a P/E ratio of 24.0x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (61)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.01B
P/E Ratio24
Dividend YieldN/A
52 Week High3.43
52 Week Low1.6
Last AnnualDecember
IPO Date7/12/2016
IncorporatedUSA
Shares Outstanding383M
No. of Employees459
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
Beta1.184
CurrencyUSD
Websitethecronosgroup.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.